List of Personalized Medicine Companies in Australia - 5

Anatomics is a medical technology company that has been manufacturing high-quality medical devices, prosthetics and software solutions since 1995. Based in Melbourne Australia, Anatomics manufactures high quality patient specific implants for global distribution and in-licenses novel technology for Australian and New Zealand distribution. We strive to be recognised as a trusted and innovative provider of quality surgical products. Our mission is to work in partnership with healthcare professionals and medical device companies to provide the highest quality surgical products. We are a company of experienced and dedicated team members who strive for better surgical outcomes by initiating internal product developments and searching the world for the latest innovations in technology to make surgical procedures more effective for our partners and more comfortable for their patients.

Cardiex Limited (ASX:CDX) is a medical technology company listed on the ASX, focusing on non-invasive vascular health monitoring and digital biomarker solutions for cardiovascular disease management. The company specializes in technologies that measure arterial stiffness and central blood pressure, addressing global cardiovascular health challenges. Cardiex develops FDA-cleared medical devices and digital health solutions aimed at assessing cardiovascular risk, detecting early disease onset, and monitoring treatment efficacy. Its flagship product, the SphygmoCor® system, is recognized for measuring central aortic pressures and arterial stiffness. The company offers services such as clinical decision support, clinical trial solutions, remote patient monitoring, and research partnerships, targeting healthcare providers, clinical trials, researchers, and consumers. With a commitment to reducing the global burden of cardiovascular disease, Cardiex has seen significant revenue growth and has established partnerships to enhance wearable technology adoption. Its product lineup includes the CONNEQT Pulse, a connected vascular biometric monitor, and the Arty™ App for remote patient monitoring, among others.

As a leading radiopharmaceutical manufacturer in Australia and New Zealand, our mission at Cyclotek is to improve patient outcomes with accessible targeted radiopharmaceuticals. Our novel PET-tracers provide patient-specific insights into their disease state, providing earlier diagnosis, more accurate assessment of disease extent and improved treatment planning and motoring. Cyclotek offers a range of radiopharmaceutical products in oncology and neurology, bringing patient-centred diagnostics to life. With the unlocking of the human genome and ever more sophisticated chemistry innovation, we seek to advance therapeutic discovery, further refine diagnostic pathways and drive higher standards in personalised medicine.

Gelomics is revolutionizing drug development by enabling the growth of human tissue models in vitro, providing an ethical, cost-effective, and predictive alternative to animal testing. Our mission is to accelerate therapeutic breakthroughs, ensuring faster, safer, and more humane medical advancements.

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies. Cell Therapies OmniCAR: is a universal immune receptor platform enabling controllable cell activity and multi- antigen targeting with a single cell product. OmniCAR’s modular CAR system decouples antigen recognition from the cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to immune cells. OmniCAR is based on technology licensed from Penn and Oxford University; and other assets. Prescient is developing OmniCAR-T cells programs for next-generation CAR-T therapies for AML; Her2+ solid tumours, including breast, ovarian and gastric cancers; and GBM. CellPryme: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Targeted Therapies PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it has shown encouraging efficacy signals and safety. PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects.